» Articles » PMID: 32249069

Malignant Transformation Rate of Oral Leukoplakia-systematic Review

Overview
Publisher Elsevier
Date 2020 Apr 7
PMID 32249069
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The aim of this study was to perform a systematic review of prevalence studies to determine the rate of malignant transformation of oral leukoplakia and assess the influence of demographic factors (age, gender, and geographic region) on the overall transformation rate.

Study Design: A search was conducted for publications until July 2019 in 4 electronic databases and peer-reviewed journals. A manual search was performed on the bibliographies of the collected articles, and the authors were contacted for additional information. This study was previously registered with the trial number CRD42019126909 and study quality assessed through established methods. The results were expressed by means of proportions or odds ratios with a 95% confidence interval. Meta-regression was undertaken to evaluate possible sources of heterogeneity, and funnel plot visual analysis was performed to assess publication bias.

Results: The 34 observational epidemiologic studies included reported data on 26,209 patients with oral leukoplakia from 18 different countries. Meta-analysis of 32 studies (23,489 patients) presented an estimated overall mean proportion of malignant transformation rate of 9.70% (7.80-11.70) (I = 98.66%; τ < 0.001; χ = 23.18; degrees of freedom [df] = 31). When comparing genders, the odds ratio favored males with 0.622 (0.468-0.826) (I = 29.77%; τ = 0.089; χ = 22.78; df = 16).

Conclusions: Within the limitations of the included studies in this systematic review, the results suggest that the malignant transformation rate was dependent on demographic factors and follow-up time. Future studies should include the development of guidelines to standardize the methodology for long-term follow-up assessment, thus reducing the risk of bias.

Citing Articles

HOXC-AS1 and EZH2 interaction increase HOXC9 expression and promote the malignant transformation of oral leukoplakia.

Chen X, Han J, Li S, Yang X, Yang S, Xu C J Cancer. 2025; 16(4):1202-1214.

PMID: 39895798 PMC: 11786031. DOI: 10.7150/jca.103482.


Microbial molecules, metabolites, and malignancy.

Thomas R Neoplasia. 2025; 60:101128.

PMID: 39827500 PMC: 11787689. DOI: 10.1016/j.neo.2025.101128.


Clinical Management Update of Oral Leukoplakia: A Review From the American Head and Neck Society Cancer Prevention Service.

Gates J, Abouyared M, Shnayder Y, Farwell D, Day A, Alawi F Head Neck. 2024; 47(2):733-741.

PMID: 39584361 PMC: 11717973. DOI: 10.1002/hed.28013.


Recurrence in Oral Leukoplakia: A Systematic Review and Meta-analysis.

Bhattarai B, Singh A, Singh R, Chaulagain R, Soland T, Hasseus B J Dent Res. 2024; 103(11):1066-1075.

PMID: 39290142 PMC: 11504345. DOI: 10.1177/00220345241266519.


Epidemiological Trends and Clinicopathological Characteristics of Oral Leukoplakia: A Retrospective Analysis From a Single Institution in Chennai, Tamil Nadu, India.

Prabhu Venkatesh D, Ramalingam K, Ramani P, Krishnan M, Kumar Vadivel J Cureus. 2024; 16(6):e61590.

PMID: 38962636 PMC: 11221497. DOI: 10.7759/cureus.61590.